This study aims to learn more about the effects of naproxen and aspirin on the normal colon in people with Lynch syndrome. By doing this study, the study team hopes to gather information on the safety and effectiveness of naproxen and/or aspirin for the use of cancer immune interception in Lynch syndrome. Naproxen or aspirin may help to prevent the development of cancerous cells in the colon.   
  

This clinical trial is for adult participants who have advanced blood cancer that has been previously treated and is now unresponsive.
   
The purpose of this study is to learn more about the safety and effectiveness of using an investigational drug, NC525, in the treatment of blood cancer. An “Investigational” drug means it has not been approved for marketing by any health authority including the U.S. Food and Drug Administration (FDA).
   

This clinical trial is for adult participants who have a diagnosis of immune-mediated thrombotic thrombocytopenic purpura (iTTP).
   
The purpose of this study is to find out if an investigational study drug called TAK-755 is effective in treating iTTP with and without the current standard-of-care (SoC) treatment, which is daily plasma exchange (PEX). The purpose is also to find out how safe TAK-755 is, what are the side effects that might be related to it, and how often do they occur.
   

This study is evaluating whether position emission tomography (PET) imaging of the brain using 18F-FES can better detect and better provide targeted treatment of brain metastases in patients with endocrin resistant (ER)-positive breast cancer.  

This study is being done to identify if there is a safe, tolerable, and effective schedule of pomalidomide treatment when it is given in combination after induction therapy with daunorubicin and cytarabine liposome for acute myeloid leukemia (AML). Additionally, the study will evaluate if the combination of pomalidomide and daunorubicin and cytarabine liposome induction therapy is more effective in controlling AML than induction therapy with daunorubicin and cytarabine liposome alone.
   

This study is being done to evaluate if adding the drug ipatasertib to the usual approach is able to safely lower the chance of head and neck squamous cell cancer growing or spreading. This study aims to determine if this approach is better or worse than the usual approach.

The usual approach consists of treatment with immunotherapy using pembrolizumab. Pembrolizumab is approved by the U.S. Food and Drug Administration (FDA) and is administered through a vein in the arm.

This study is being done to find better ways to diagnose, treat and prevent cancers in children, adolescents, and young adults. To do this, we need to learn more about cancers that happen to these groups. As most cancers that children get are rare, we can best learn by combining information from as many children with cancer as possible.

This study aims to improve outcomes for patients with NCI High Risk B-Cell Acute Lymphoblastic Leukemia (B-ALL) and patients with NCI Standard Risk B-ALL with high risk features. High risk features are when the leukemia has spread to the spinal fluid or testes, or one received steroid treatment before being diagnosed with leukemia.
   

This clinical trial is for men and women with newly diagnosed or relapsed/refractory acute myeloid leukemia.

The purpose of this study is to determine a safe dose of an investigational new drug (ziftomenib) in combination with other study drugs i.e., venetoclax and azacitidine or cytarabine plus daunorubicin. This will include an evaluation of side effects associated with ziftomenib in combination with the other study drugs and also aims to determine how ziftomenib works in combination with the other study drugs.

This clinical trial is for adult participants who have pancreatic ductal adenocarcinoma or colorectal cancer with a specific type of mutation (mKRAS or mNRAS) present in their cancer.